Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor

Drug–drug interaction (DDI) studies are described for tezacaftor/ivacaftor, a new cystic fibrosis transmembrane conductance regulator modulator therapy for the treatment of cystic fibrosis. Three phase I DDI studies were conducted in healthy subjects to characterize the DDI profile of tezacaftor/iva...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Transl Sci
Glavni autori: Garg, Varun, Shen, Jinshan, Li, Chonghua, Agarwal, Sagar, Gebre, Asfiha, Robertson, Sarah, Huang, Jiayin, Han, Linda, Jiang, Licong, Stephan, Kristin, Wang, Linda T., Lekstrom‐Himes, Julie
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510372/
https://ncbi.nlm.nih.gov/pubmed/30694595
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12610
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items